Clinical trials Below are current clinical trials.14 studies in Kidney Transplant Program (open studies only). Filter this list of studies by location, status and more. A Study of Kidney Transplant Recipients: Development of a Database for a Multicenter Consortium Rochester, Minn. The purpose of this study is to collect and share detailed clinical data from all kidney transplant recipients from 7 kidney transplant centers (Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Jacksonville, FL; Cornell University, New York, NY; University of Michigan, Ann Arbor, MI; Henry Ford, Detroit, MI; University of Pittsburgh Medical Center, Pittsburg, PA) to retrospectively and prospectively study kidney transplant recipients. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients Rochester, Minn. The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE. A Study to Evaluate the Safety of the SARS-CoV-2 Vaccination in Patients Waitlisted for Solid Organ Transplantation Jacksonville, Fla. The purpose of this study is to determine the safety of the SARS-CoV-2 vaccination in patients listed for solid organ transplantation, including heart, lung, liver, kidney, and pancreas. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Scottsdale/Phoenix, Ariz. The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes. Pagination Clinical studies PrevPrevious Page Go to page 11 Go to page 22 Request an appointment Locations, travel & lodgingResearch Oct. 31, 2024 Share on: FacebookTwitter Kidney Transplant ProgramDepartmenthomeSectionsRequest an appointmentOverviewConditions treatedDoctorsDoctors by location and specialtyExpertise & rankingsLocations, travel & lodgingClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicVolumes and outcomesEligibilityReferralsContactus Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an appointmentOverviewConditions treatedDoctorsDoctors by location and specialtyExpertise & rankingsLocations, travel & lodgingClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicVolumes and outcomesEligibilityReferrals ORG-20193489 Medical Departments & Centers Kidney Transplant Program